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ABSTRACT. Diabetes mellitus is a common endocrine disease of dogs and cats. Treatment is mainly based on insulin 
administration and dietary modifications. The aim of this review is to provide updated information on insulin treatment 
of dogs and cats with non-complicated diabetes mellitus. During the last years, there has been significant progress in 
the management of this disease, thanks to the use of long-acting insulin preparations that do not cause pronounced 
fluctuations of blood glucose concentrations (insulin glargin and detemir) and because of the widespread use of home 
glucose monitoring by the owners of diabetic pets. Home glucose monitoring is based on capillary blood sampling from 
the ear pinnae or the foot pad and measurement of blood glucose concentration with a portable blood glucose meter. 
This can be done periodically (e.g. every week) to replace the traditional in-clinic blood glucose curve; in this case, 
blood glucose concentration is measured just before the morning insulin administration and then every 1-2 hours until 
the next dose (usually for 12 hours). Furthermore, especially for the cat, home glucose monitoring can be performed 
3-5 times per day, on a daily basis, in order to safely adjust insulin dose and achieve tight control of hyperglycemia (i.e. 
blood glucose concentration between 50 and 200 mg dl-1 throughout the day). The combination of dietary management, 
of insulin glargine or detemir administration and of the tight control of hyperglycemia has substantially increased the 
proportion of cats that enter into temporal or permanent diabetic remission and can be further managed without insulin. 
Another important achievement is the use of continuous glucose monitoring systems to monitor interstitial fluid glucose 
concentrations. These devices can be used in the clinic and at home and they can measure glucose concentration every 5 
minutes for up to 72 consecutive hours, thus facilitating optimal adjustment of insulin treatment.
Keywords: cat; detemir; diabetes mellitus; diabetic remission; dog; glargin; insulin
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INTRODUCTION
Diabetes mellitus (DM) is one of the most com-mon endocrine diseases of dogs and cats. 
Canine DM is typically the result of decreased 
insulin secretion by pancreatic b-cells (type I DM) 
whereas feline DM is usually attributed to decreased 
insulin sensitivity (type II DM). Despite the different 
pathogenesis, initial treatment of both dogs and cats 
with non-complicated DM is mainly based on insulin 
administration along with dietary modification. The 
aims of the treatment are to: a) control the clinical 
manifestations of the disease, b) avoid complica-
tions of DM such as diabetic ketosis and acidosis, 
cataract formation (especially in dogs) and polyneu-
ropathy (especially in cats), c) control blood glucose 
concentrations throughout the day, ideally below 
the renal threshold for glycosuria (i.e. 175-220 mg 
dl-1 for dogs and 210-290 mg dl-1 for cats), d) avoid 
treatment complications, especially hypoglycemia, 
e) improve the quality of life of the diabetic dog or 
cat and the owner, and f) achieve diabetic remission 
in cats (Martin and Rand, 2007a; Zerrenner et al., 
2007; Marshall et al., 2009; Niessen et al., 2010, 2012; 
Smith et al., 2012; Caney, 2013).
The aim of this article is to review recent develop-
ments in insulin treatment of dogs and cats with non-
complicated DM, including the use of new types of 
insulin (glargin and detemir), techniques to accurately 
administer low doses of undiluted insulin, schedules of 
blood glucose monitoring by the owner at home setting, 
continuous glucose monitoring systems and, finally, 
protocols to tightly control blood glucose concentra-
tions with the aim of diabetic remission in cats.
TYPES OF INSULIN FOR DOGS AND CATS 
WITH NON-COMPLICATED DIABETES 
MELLITUS
Insulin is a 51 amino acid protein with two chains: 
the A chain consists of 21 amino acids (A1 to A21) and 
the B chain of 30 amino acids (B1 to B30) (Zerrenner et 
ΠΕΡΙΛΗΨΗ. Ο σακχαρώδης διαβήτης είναι μια συχνή ενδοκρινοπάθεια στους σκύλους και τις γάτες και η θεραπευτική 
του αντιμετώπιση στηρίζεται κυρίως στη χορήγηση ινσουλίνης και τα διαιτητικά μέτρα. Σκοπός της ανασκόπησης 
αυτής είναι η ενημέρωση του κλινικού Κτηνιάτρου για τα σύγχρονα δεδομένα της θεραπείας με ινσουλίνη σε σκύλους 
και γάτες με απλό σακχαρώδη διαβήτη. Τα τελευταία χρόνια έχει αλλάξει σημαντικά η θεραπευτική προσέγγιση του 
νοσήματος, χάρη στη χρησιμοποίηση ινσουλινών με μεγάλη και σταθερή διάρκεια δράσης που δεν προκαλούν έντονη 
αυξομείωση της συγκέντρωσης της γλυκόζης στο αίμα (ινσουλίνη glargine και detemir) και στην ευρεία εφαρμογή της 
μέτρησης της συγκέντρωσης της γλυκόζης στο αίμα από τον ιδιοκτήτη του ζώου, στο σπίτι. Η τελευταία γίνεται με 
τη βοήθεια γλυκοζόμετρου, ύστερα από λήψη τριχοειδικού αίματος από το πτερύγιο του αυτιού ή το πελματικό φύμα. 
Οι μετρήσεις στο σπίτι πραγματοποιούνται περιοδικά (π.χ. σε εβδομαδιαία βάση), κάθε 1-2 ώρες για το μεσοδιάστημα 
μεταξύ δυο διαδοχικών χορηγήσεων ινσουλίνης (συνήθως 12 ώρες), αντικαθιστώντας έτσι την καμπύλη γλυκόζης 
που γινόταν στην κλινική. Επιπλέον, στις γάτες έχει προταθεί να γίνονται 3-5 φορές ημερησίως, σε καθημερινή βάση, 
προκειμένου να επιτευχθεί με ασφάλεια ο στενός έλεγχος της υπεργλυκαιμίας (μεταξύ 50 και 200 mg dl-1 καθ’ όλη τη 
διάρκεια της ημέρας) με συνεχείς τροποποιήσεις της δόσης της ινσουλίνης. Μάλιστα, με το συνδυασμό των διαιτητικών 
μέτρων, της χορήγησης ινσουλίνης glargine ή detemir και του στενού ελέγχου της υπεργλυκαιμίας έχει αυξηθεί 
σημαντικά ο αριθμός των γατών εκείνων όπου επιτυγχάνεται προσωρινή ή μόνιμη ύφεση του σακχαρώδη διαβήτη, 
γεγονός που επιτρέπει τη διακοπή της χορήγησης ινσουλίνης (παροδικός σακχαρώδης διαβήτης). Μια ακόμα ελπιδοφόρα 
εξέλιξη είναι η ολοένα και συχνότερη χρησιμοποίηση των συσκευών συνεχούς μέτρησης της συγκέντρωσης της 
γλυκόζης στον υποδόριο ιστό. Χάρη στις συσκευές αυτές, που μπορούν να χρησιμοποιηθούν τόσο στην κλινική όσο και 
στο σπίτι, υπάρχει η δυνατότητα να μετράται η συγκέντρωση της γλυκόζης κάθε 5 λεπτά για χρονικό διάστημα μέχρι και 
72 συνεχόμενων ωρών, γεγονός που επιτρέπει την καλύτερη ρύθμιση της θεραπείας με ινσουλίνη.
Λέξεις ευρετηρίασης: γάτα, ινσουλίνη detemir, ινσουλίνη glargine, παροδικός σακχαρώδης διαβήτης, σκύλος
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al., 2007). Differences in the biological effects among 
insulin preparations depend on the origin of insulin 
(recombinant human, porcine or bovine), addition of 
zinc or protamine [lente, neutral protamine Hagedorn 
(NPH) or isophane, protamine zinc insulin (PZI)] and 
changes of insulin’s molecular structure (glargine, 
detemir) (Zerrenner et al., 2007; Mori et al., 2008; Flee-
man et al., 2009; Clark et al., 2012).
Various types of recombinant human insulin are 
widely available and they differ from canine and from 
feline insulin by one and four amino acids, respectively 
(Zerrenner et al., 2007; Rios and Ward, 2008). Porcine 
insulin has exactly the same amino acid sequence 
with canine insulin but differs from feline insulin by 
three amino acids (Rios and Ward, 2008; Fleeman et 
al., 2009). The closest available insulin to that of cats 
is bovine insulin because it differs by only one amino 
acid; also bovine insulin has quite similar molecular 
structure with that of canine insulin with differences in 
two amino acids (Davison et al., 2008; Rios and Ward, 
2008) (Table 1). Recombinant human, porcine and 
bovine insulins are effective in lowering blood glucose 
concentrations of diabetic dogs and cats. Therefore, the 
importance of insulin origin is related to the potential 
of anti-insulin antibodies production due to administra-
tion of a heterologous protein (Fleeman et al., 2009). A 
mixed bovine-porcine PZI and a bovine lente insulin 
may induce anti-insulin antibodies in dogs (Cook, 2007; 
Zerrenner et al., 2007; Davison et al., 2008) and such 
antibodies were detected more frequently in diabetic 
dogs treated with bovine PZI (85%) or bovine lente 
(56%) insulin compared to those treated with a porcine 
lente insulin (12%), whereas there was no difference 
between the latter and the control group that included 
both healthy dogs and non-diabetic sick dogs (Davison 
et al., 2008). On the other hand, a negative impact of 
anti-insulin antibodies on the glycemic control of dogs 
and cats with DM has not been proven so far (Davison 
et al., 2008). Therefore, the origin of insulin is not cur-
rently considered a decisive factor for selecting insulin 
for a diabetic pet.
Insulin lente contains zinc and consists of amor-
phous (30%) and of crystalline insulin (70%); currently 
there are is only one commercially available veterinary 
preparation (Caninsulin®, MSD) of porcine origin at 
a strength of 40 U ml-1 (Davison et al., 2008; Caney, 
2013). Another veterinary preparation of bovine origin 
(Insuvet® Lente, 100 U ml-1, originally distributed by 
Schering-Plough and later by Pfizer Animal Health) 
is not available anymore and the same applies to most 
recombinant human insulin lente preparations (Zer-
renner et al., 2007; Davison et al., 2008). At least in 
theory, two peaks in the action and thus in the glucose 
lowering effect are to be expected, one occurring soon 
after subcutaneous (SC) administration and attributed 
to the amorphous insulin part and the second occur-
ring later due to the crystalline insulin part of insulin 
lente (Cook, 2007; Zerrenner et al., 2007; Fleeman et 
al., 2009). However, the pharmacokinetics and phar-
macodynamics exhibit considerable between-patient 
as well as day-to-day variation (Fleeman et al., 2009). 
For example, in a group of eight dogs with stable DM, 
onset of action occurred 1.5-6h (average: 3h) after SC 
administration, time to nadir (lowest blood glucose 
concentration) ranged from 4 to 22h (average: 8h) and 
the time period that blood glucose concentrations were 
bellow renal threshold varied from 10h to more than 
24h (average: 14h) (Fleeman et al., 2009). In normal 
cats, onset of action occurs after approximately 1h, 
time to nadir is 3-6h (average: 4.7h) and the duration 
of action is usually 8-10h (Marshall et al., 2008; Caney, 
2013). The most important drawbacks of insulin lente 
in diabetic cats is the fast rate of decrease in blood glu-
cose concentrations, which may trigger counter regula-
tory mechanisms, along with the 2-6h time period of 
high blood glucose concentration that occurs between 
two consecutive administration at 12h intervals (Mar-
shall et al., 2008). 
Origin of commercially available insulin preparations
Human Porcine Bovine
Dog 1 0 2
Cat 4 3 1
Table 1. Number of amino acids that differ between the insulin of dogs or cats and the commercially available insulin preparations of 
different origin
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side effect is hypoglycemia that may (clinical hypo-
glycemia) or may not (biochemical hypoglycemia) 
be accompanied by clinical signs and occurs more 
frequently at higher doses (Michiels et al., 2008).
Insulin NPH contains zinc and protamine (a 
strongly basic protein extracted from salmon testes) 
that both prolong the duration of action and result in 
a solution of free and protamine-bound insulin (Zer-
renner et al., 2007; Mori et al., 2008). Currently, only 
recombinant human insulin NPH is available since 
porcine and bovine-origin preparations have been 
withdrawn from the market (Zerrenner et al., 2007; 
Palm et al., 2009). Similarly to insulin lente, pharma-
cokinetics and pharmacodynamics exhibit considerable 
dog to dog variation, the peak activity occurs at 5h 
(1-10h in individual dogs) and the duration of action 
ranges from 4-24h (average 5.5h) (Mori et al., 2008; 
Palm et al., 2009; Clark et al., 2012). In cats, due to its 
short duration of action, insulin NPH results in poor 
glycemic control when administered BID (Zerrenner et 
al., 2007). Insulin NPH is commonly used for the treat-
ment of canine DM, especially overseas (Aptekmann 
and Schwartz, 2011), and less frequently for feline DM, 
at an initial dose of 0.25-0.5 U kg-1 BID that can be sub-
sequently increased by 10-15% or decreased by 25% 
in case of persistent hyperglycemia (>250 mg dl-1) or 
hypoglycemia (<70 mg dl-1), respectively (Cook, 2007; 
Zerrenner et al., 2007; Sako et al., 2011).
Insulin PZI contains zinc and protamine (at a 
higher quantity compared to insulin NPH) that form 
complexes with the insulin molecule; these complexes 
precipitate at the neutral pH of the SC tissue, slowly 
dissociate by the action of proteolytic enzymes and the 
released insulin is subsequently absorbed (Zerrenner 
et al., 2007; Rios and Ward, 2008; Clark et al., 2012; 
Scott-Moncrieff et al., 2012). Bovine (Insuvet® PZI, 100 
U ml-1, originally distributed by Schering-Plough and 
later by Pfizer Animal Health) and 90% bovine-10% 
porcine (PZI Vet®, 40 U ml-1, Idexx Laboratories) 
preparations are no longer available, but there is a 
human recombinant insulin PZI veterinary prepara-
tion (ProZincTM, 100 U ml-1 Boehringer Ingelheim) 
that has been registered for treatment of feline DM 
(Davison et al., 2008; Nelson et al., 2009; Clark et al., 
2012; Scott-Moncrieff et al., 2012; Smith et al., 2012; 
Caney, 2013; Roomp and Rand, 2013). Once again, 
pharmacokinetics and pharmacodynamics are highly 
variable: onset of action occurs between 0.5h and 14h 
Insulin lente has been used for many years in the 
management of dogs and cats with non-complicated 
DM (Aptekmann and Schwartz, 2011). Contrary to the 
manufacturer’s recommendations proposing a starting 
dose of 0.75-1 U kg-1 once daily (SID) and despite the 
fact that most clinicians start at 0.25 U kg-1 every 12h 
(BID), based on the available pharmacokinetic and 
pharmadynamic information Caninsulin® treatment of 
diabetic dogs should start at 0.5 U kg-1 BID and sub-
sequently gradually increased, each time by 10-15%, 
in case of persistent hyperglycemia (blood glucose 
concentrations >250 mg dl-1) or decreased by 25% in 
case of tendency for hypoglycemia (blood glucose 
concentration <70 mg dl-1) or relatively low (<180 mg 
dl-1) blood glucose concentration immediately before 
insulin administration (Cook, 2007; Zerrenner et al., 
2007; Fleeman et al., 2009). For cats, current recom-
mendations on the initial dose vary from 1-2 U per cat 
BID to 0.25 to 0.5 U kg-1 of ideal body weight BID with 
a maximum of 3 U per cat (the higher end of the dose 
range is preferable for cats with a blood glucose con-
centration >340-360 mg dl-1) (Martin and Rand, 2007b; 
Michiels et al., 2008; Marshall et al., 2009; Tschuor 
et al., 2011; Caney, 2013). Subsequent dose modifica-
tions are typically based on blood glucose curves that 
should be performed every 1-2 weeks: depending on 
the therapeutic protocol (i.e. aiming at diabetic remis-
sion or not) dose will be increased by 0.5-1 U per cat 
when blood glucose concentrations are higher than a 
predetermined value (i.e. 160 mg dl-1 with protocols 
to achieve disease remission) and it will be decreased 
by 0.5 to more than 1 U per cat or by 50-75% in case 
of biochemical (<50 mg dl-1) or clinical hypoglycemia 
with or without skipping the next dose (Martin and 
Rand, 2007b; Michiels et al., 2008; Tschuor et al., 2011; 
Caney, 2013). An alternative way to rapidly adjust the 
initial dose of diabetic cats is to hospitalize them and 
perform daily 12h glucose curves for the first three 
days of treatment: the dose will be decreased by 50%, 
by 1 U per cat or by 0.5 U per cat if the nadir is <50 
mg dl-1, 50-90 mg dl-1 and 90-120 mg dl-1, respectively 
(Marshall et al., 2009). 
Depending on the protocol and study population, 
insulin lente is generally effective in controlling blood 
glucose concentrations and clinical signs of dogs 
and cats with non-complicated DM but it is not very 
likely to induce diabetic remission (see later), even 
in newly diagnosed diabetic cats (Martin and Rand, 
2007b; Michiels et al., 2008). As expected, the major 
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post-administration in dogs, peak action may be wit-
nessed between 5h to more than 24h (average: 13-16h) 
in dogs and between 1h and 12h (average: 3.74.6h) in 
cats and the duration of action, which is usually longer 
than for insulin NPH, may range from 16h to more than 
24h in dogs and from 8h to 24h in cats (Zerrenner et al., 
2007; Marshall et al., 2008; Rios and Ward, 2008; Nel-
son et al., 2009; Clark et al., 2012). Besides its common 
use, especially in U.S.A. (Smith et al., 2012), insulin 
PZI is not typically recommended for dogs because of 
the highly unpredictable onset and duration of action 
and the lack of a benefit compared to other available 
preparations; however, it may be tried in selected cases 
experiencing difficulties in the management of DM due 
to the shorter duration of action of insulin Lente and 
NPH (Cook, 2007; Zerrenner et al., 2007; Maggiore 
et al., 2012). In cats it is used much more commonly, 
despite the possible appearance of a biphasic blood 
glucose curve, that may reflect activation of counter 
regulatory mechanisms secondarily to a fast decline 
of blood glucose concentration(Marshall et al., 2008).
When used to treat diabetic dogs, the usual start-
ing dose is 0.5 U kg-1 BID and the adjusted dose that 
was needed to control the clinical signs ranged from 
0.4 to 1.5 U kg-1 (Maggiore et al., 2012). However, 
some dogs may need SID administration; when nadir 
occurs at the beginning or the end of the 12h blood 
glucose curve or when Somogyi response is sus-
pected, there is a clear indication to switch from BID 
to SID treatment (Maggiore et al., 2012). For diabetic 
cats, initial dose recommendations vary: 0.25-0.5 U 
kg-1 BID with the higher end of the dose range used in 
cats with blood glucose concentrations >360 mg dl-1 or 
0.22-0.66 mg kg-1 BID with the lower dose selected in 
newly diagnosed cases or 1-3 U per cat BID have all 
been suggested (Cook, 2007; Zerrenner et al., 2007; 
Marshall et al., 2009; Nelson et al., 2009). Similarly 
to insulin lente, rapid adjustment of the initial dose 
can be achieved if the cats are hospitalized for three 
days and daily 12h glucose curves are performed: the 
dose is decreased by 50%, by 1 U per cat or by 0.5 U 
per cat if the nadir is <50 mg dl-1, 50-90 mg dl-1 and 
90-120 mg dl-1, respectively and it is decreased to 1 
U per cat SID for those cats that are treated with 1 U 
per cat BID and blood glucose concentrations before 
insulin administration are <210 mg dl-1 (Marshall 
et al., 2009). In general, like in dogs, insulin PZI 
treated cats may be controlled with SID administra-
tion, especially when nadir occurs 10h after injection 
or later and when Somogyi response is witnessed 
(Cook, 2007; Zerrenner et al., 2007; Nelson et al., 
2009). The efficacy of insulin PZI for the control of 
hyperglycemia and of clinical signs of DM seems 
to be comparable to those of insulin lente and NPH: 
in two recent studies 82% of diabetic dog owners 
considered that their pet’s condition had improved 
after 2 months, whereas good diabetic control was 
achieved in 85% of the cats in a 45 day period (Nelson 
et al., 2009; Maggiore et al., 2012). The incidence of 
hypoglycemia clearly depends on the dose and was 
recorded in 12-18% of the dogs and in up to 64% of 
the cats in the same studies (Nelson et al., 2009; Mag-
giore et al., 2012).
Insulin glargine (Lantus®, 100 U ml-1, Sanofi-
Aventis) is a recombinant human insulin analogue: 
asparagine has been replaced by glycine at the 23rd 
amino acid position of the A chain and two arginine 
amino acids have been added at the C-terminus of 
the B chain (Zerrenner et al., 2007; Gilor et al., 2010; 
Roomp and Rand, 2013). In the acidic (pH: 4) com-
mercially available solution, insulin glargine is water 
soluble but after its injection into SC tissues, where 
pH is neutral, insulin crystals precipitate thus delay-
ing absorption that remains steady over time (Mori et 
al., 2008; Gilor et al., 2010; Roomp and Rand, 2013). 
The pH-dependency is the reason why dilution or 
mixing with other insulin preparations is not allowed 
and also explains why insulin glargine acts like short-
acting regular insulin if administered intravenously or 
intramuscularly (Zerrenner et al., 2007; Marshall et al., 
2008; Roomp and Rand, 2013). The unopened vial can 
be stored at the refrigerator for up to 6 months but once 
open, it is stored at room temperature for one month 
(Zerrenner et al., 2007; Roomp and Rand, 2013). In 
humans, insulin glargine is marketed as “basal” insulin 
without significant peaks and troughs that mimics nor-
mal pancreatic insulin secretion between meals but it is 
not clear if the same applies to both diabetic dogs and 
cats. In dogs with DM, lack of significant differences 
among blood glucose concentrations at 2h, 4h, 6h and 
8h after administration indicate a relative lack of peaks 
in insulin’s action (Hess and Drobatz, 2013) but in other 
studies peaks have been witnessed, usually 6-10h post-
injection (Mori et al., 2008; Fracassi et al., 2012); also 
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blood glucose curves for the first one to three days of 
treatment, using one of the following three protocols: 
Protocol 1: the dose is decreased by 50%, or by 1 U per 
cat or by 0.5 U per cat if the nadir is <50 mg dl-1, 50-90 
mg dl-1 and 90-120 mg dl-1, respectively; also the dose 
remains the same but the frequency of administration 
is decreased to SID for those cats that are treated with 
1 U per cat BID if blood glucose concentrations before 
insulin administration are <210 mg dl-1 (Marshall et al., 
2009). Protocol 2: the dose is decreased or increased 
by 0.5-1 U per cat if the nadir is <90 mg dl-1 or >160 
mg dl-1, respectively (Tschuor et al., 2011). Protocol 3: 
the dose is decreased by 1 U per cat if the nadir is <70 
mg dl-1 (Cook, 2007). Like every insulin preparation 
the typical side effect is hypoglycemia, which is more 
frequently biochemical rather than clinical and can be 
witnessed in up to 70% of treated animals (Marshall et 
al., 2009; Fracassi et al., 2012; Hess and Drobatz, 2013).
Most dogs with DM can be controlled with insulin 
glargine but due to the limited scientific information 
it is unclear whether this treatment is superior to that 
with insulin lente or NPH (Fracassi et al., 2012; Hess 
and Drobatz, 2013). On the contrary, in diabetic cats 
insulin glargine treatment is clearly superior and car-
ries an increased potential for diabetic remission (see 
later) compared to insulin lente and PZI (Marshall et 
al., 2009; Roomp and Rand, 2009) which explains why, 
despite its recent introduction into the market and lack 
of a veterinary formulation, it is the preferred insulin 
for treatment of feline DM for more than 25% of the 
veterinarians in the U.S.A. (Smith et al., 2012). How-
ever, a recent analysis did not demonstrate a benefit of 
insulin glargine over insulin lente of porcine origin in 
terms of the duration of survival of diabetic cats (Cal-
legari et al., 2013)
Insulin detemir (Levemir®, 100 U ml-1, Novo Nor-
disk) is also a recombinant human insulin analogue 
where threonine has been removed from the C-terminal 
of B chain and myristic acid has been bound to the 
lysine which is 29th amino acid of the same chain (Gilor 
et al., 2010; Sako et al., 2011; Roomp and Rand, 2012; 
Roomp and Rand, 2013). These molecular changes 
result in a slowly absorbed and highly albumin-bound 
molecule with long duration of action and increased 
the duration of action was found to be 24h in normal 
dogs and the blood glucose lowering-effect is similar 
or slightly lower compared to insulin NPH (Mori et al., 
2008; Sako et al., 2011). In cats pharmacokinetics and 
pharmacodynamics vary between patients so that a 
clear nadir of blood glucose concentration may or may 
not be seen; onset of action occurs after approximately 
1-2h, glucose nadir may be seen any time between 2.5 
and 16h, sometimes a biphasic action with an early 
and a late nadir is noticed and the duration of action 
varies between 7h and 24h but in most cats it exceeds 
12h (Marshall et al., 2008; Rios and Ward, 2008; 
Roomp and Rand, 2009; Gilor et al., 2010; Smith et al., 
2012). Also, potency (blood glucose lowering effect) of 
insulin glargin is generally similar but is some cats it 
may be lower than that of insulin lente, NPH and PZI 
(Marshall et al., 2008; Roomp and Rand, 2009; Ford 
and Lynch, 2013; Roomp and Rand, 2013). 
Initial dose range for diabetic dogs is 0.25-0.5 
U kg-1 BID (Fracassi et al., 2012) but the results of a 
recent study indicate that 0.3 U kg-1 BID is probably 
a safe starting point, taking into consideration the 
high incidence of hypoglycemia at higher doses (Hess 
and Drobatz, 2013). At subsequent examinations the 
initial dose may have to be increased or decreased by 
5-20% or by 0.001-0.2 U kg-1, each time depending 
on the amelioration of clinical signs (if not, dose is 
increased) and the results of blood glucose curves (if 
constantly >200 mg dl-1 the dose is increased, whereas 
even a single value <80 mg dl-1 is a clear indication 
for dose decrement) (Fracassi et al., 2012; Hess and 
Drobatz, 2013). Based on a limited body of informa-
tion the final optimal dose of the control of canine DM 
ranges between 0.1 and 1.1 U kg-1 but it is typically 
around 0.5-0.6 U kg-1 (Fracassi et al., 2012; Hess and 
Drobatz, 2013). For cats with DM insulin glargine 
treatment is started at 0.25-0.5 U kg-1 BID (the upper 
end of the dosing regimen is used when blood glucose 
concentration exceeds 360 mg dl-1) or at 1-2 U per cat 
BID depending on the ideal body weight (1 U if ≤4 
kg and 1.5-2 U if >4 kg) (Cook, 2007; Rios and Ward, 
2008; Hall et al., 2009; Marshall et al., 2009; Tschuor 
et al., 2011). Some investigators advocate to adjust the 
initial dose by hospitalizing cats and performing serial 
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liver penetration (Gilor et al., 2010; Sako et al., 2011; 
Roomp and Rand, 2012; Roomp and Rand, 2013) which 
is also very stable and can be used for up to 6 weeks 
after opening if kept at room temperature and up to 
6 months if refrigerated (Roomp and Rand, 2013). In 
normal dogs peak activity is witnessed at 8-10h and the 
duration of action is more than 24h (Sako et al., 2011), 
whereas the respective figures in cats are 5-9h (aver-
age: 7h) and 9-14h (average: 12h) (Gilor et al., 2010). 
In general the pharmacokinetics vary among cats, the 
time-action profile can either be long-acting without 
peaks or shorter-acting with a demonstrable nadir of 
blood glucose concentration and the duration of action 
is shorter compared to humans (Gilor et al., 2010). From 
the pharmacodynamic point of view, insulin detemir is 
probably of lower potency compared to insulin NPH 
and glargine in dogs, and in cats it is of lower potency 
compared to insulin lente, NPH and PZI but of similar 
potency to insulin glargine (Gilor et al., 2010; Sako et al., 
2011; Roomp and Rand, 2012; Roomp and Rand, 2013).
The recommended starting dose for both diabetic 
dogs and cats is 0.25-0.5 U kg-1 BID although the opti-
mal dose can be substantially lower (Sako et al., 2011). 
The efficacy of insulin detemir for the management of 
canine DM seems to be adequate and it may prove to 
be superior to other insulin types, although the risk 
of hypoglycemia may be increased (Sako et al., 2011; 
Maggiore et al., 2012), whereas in cats it appears to be 
comparable to insulin glargine when intensive proto-
cols aiming to diabetic remission are employed (see 
later). An additional indication to use insulin detemir 
may be the prevention of DM in non-diabetic dogs with 
pituitary-dependent hyperadrenocorticism and mild 
hyperglycemia (>100 mf dl-1) but additional studies 
are needed to confirm the safety and efficacy of such 
as approach (Miceli et al., 2012). 
TECHNIQUES TO ACCURATELY ADMINIS-
TER LOW DOSES OF UNDILUTED INSULIN
Insulin is usually administered with specific 
syringes and although BID SC injections are typically 
needed for life, most dogs tolerate the injections very 
well and owners can give them without the need for an 
assistant (Aptekmann and Schwartz, 2011). However, 
accurate measurement of undiluted insulin dose can be 
problematic in small dogs and in cats, especially with 
the current protocols for tight control of hyperglycemia 
(see later). In such cases, use of small volume U-100 
insulin syringes, counting the number of drops cor-
responding to 2 insulin units, use of insulin pens or 
insulin rulers and dilution of insulin (if possible) may 
help the owner to administer the intended insulin dose.
Insulin syringes are available at two forms: U-40 
and U-100. The former have a volume capacity of 1ml, 
they are marketed only for 40 U ml-1 insulin prepara-
tions, like Caninsulin® and each line corresponds to 
0.025ml that equals to 1 U of insulin. Therefore, when 
using such syringes the lowest possible increment or 
decrement of the dose is 1 U (Caney, 2013). On the con-
trary, U-100 syringes are available at a volume capacity 
of 0.3ml, 0.5ml and 1ml and each line corresponds to 
0.01ml and thus to 1 U of a 100 U ml-1 insulin or to 
0.4 U of a 40 U ml-1 insulin preparation. This offers 
a clear advantage for small dogs and cats treated with 
a 40 U ml-1 insulin preparation (permits 0.4 U dose 
changes) whereas small volume syringes (i.e. 0.3ml) 
are preferable when the same patients are treated with 
100 U ml-1 insulin because they may enable the owner 
to implement 0.5 U dose changes (Cook, 2007; Smith 
et al., 2012). However, even with the 0.3ml U-100 
syringes there is considerable variability in the admin-
istered dose that is typically higher than the intended 
one (Smith et al., 2012), partially because the printed 
scale on the syringe is not always accurate (Roomp 
and Rand, 2013).
Another technique that has been proposed to accu-
rately administer small insulin doses is based on 
counting the number of drops that correspond to 2 
insulin units. In this technique a specific brand and 
volume capacity U-100 insulin syringe is selected and 
constantly used. The owner is trained to drawn 2 U into 
the syringe (e.g. to fill the first 2 lines of the syringe 
with an 100 U ml-1 insulin preparation), to hold the 
syringe vertically with the needle pointing downwards 
and to apply constant pressure on the plunger while 
counting the number of drops until the syringe is empty 
(Roomp and Rand, 2013). This is repeated numerous 
times until the same number of drops is counted repeat-
edly (Figure 1). For example, if 2 U correspond to eight 
drops, each drop contains 0.25 U and this facilitates 
administration of a dose as low as 0.25 U as well as 
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0.25 U dose changes. In the above example, if 0.5 U 
insulin must be administered to a diabetic cat, 2 U are 
drawn into the syringe, six drops are discarded and the 
insulin that remains into the syringe corresponds to 
two drops and thus to 0.5 U. In the same cat the dose 
can be decreased to 0.25 U or increased to 0.75 U by 
discarding seven or five drops, respectively. 
Both human and veterinary-purpose insulin pens 
are available (Caney, 2013). For veterinary-purpose 
pens caution is advised on the strength of the insulin 
preparation for which each pen has been designed, 
because if a U-40 pen is used for a 100 U ml-1 insulin 
preparation the administered dose will be 2.5 higher. 
Human-purpose pens are U-100, the pediatric ones per-
mit 0.5 U dose changes and they are considered more 
accurate than 0.3ml U-100 insulin syringes (Smith et 
al., 2012; Roomp and Rand, 2013).
Insulin ruler can be freely downloaded at www.
diabetes-katzen.net/insulinruler.pdf. This ruler enables 
administration of very low doses (up to 0.1 U) of 100 
U ml-1 insulin preparations (Roomp and Rand, 2013). 
For accurate dosing, it has been recommended to use 
a sticker in order to attach the insulin vial on a vertical 
surface, to use one hand to hold the syringe and draw 
insulin and the other hand to keep the printed ruler 
next to the syringe (Roomp and Rand, 2013). Caution 
is advised since this ruler must be printed in its original 
size and is applicable only for 100 U ml-1 insulin prepa-
rations and a specific insulin syringe [Becton Dickin-
son U-100 syringes with the BD Ultra-Fine™ Needle 
0.3 ml 31Gx5/16” (8mm) with 1/2 unit markings].
When none of the above is feasible, dilution of insu-
lin just before use is the only alternative. Dilution with 
a specific diluent provided by the manufacturer or with 
normal saline or water for injection has been practiced 
for years for insulin lente, NPH and PZI 100 U ml-1 
preparations and it is also acceptable for insulin detemir 
(Roomp and Rand, 2013). Based on manufacturer’s 
instructions and its pH dependency, insulin glargine 
should not be diluted, although some specialists report 
that it may be diluted with normal saline immediately 
before administration (Roomp and Rand, 2013). When 
insulin dilution is going to be practiced by the owner 
careful education and repeated training is necessary to 
avoid dose miscalculations. According to the author’s 
experience, mistakes are common and may explain some 
cases of poor DM control and hypoglycemia.
HOME MONITORING OF BLOOD GLUCOSE 
CONCENTRATIONS BY THE OWNER
For many years treatment monitoring of diabetic 
dogs and cats has been based on frequent evaluation 
of the history (control of the cardinal clinical signs 
of DM, such as polyuria, polydipsia and polyphagia), 
body weight, physical examination findings, urinalysis, 
measurement of surrogate markers of blood glucose con-
centration over time (glycosylated hemoglobin, fructosa-
mine) and serial blood glucose curves performed at the 
hospital. In recent years there is a tendency to, at least 
partially, substitute the latter by owner-performed home 
monitoring of blood glucose concentrations. Thanks 
to the advancements of portable blood glucose meters 
(PBGMs) and the refinement of the techniques for blood 
sampling by the owner, such monitoring is feasible for 
many dogs and also for cats with DM (Niessen et al., 
2010; Ford and Lynch, 2013). The use of PBGMs, their 
indications, the factors influencing their results and 
the techniques for blood sampling have been recently 
Figure 1: Administration of low insulin doses after counting the 
number of drops that correspond to 2 insulin units. Figure 1a: 2 
units from a 100 U ml-1 insulin preparation are drawn into a U-100 
insulin syringe. Figure 1b: syringe is held vertically and constant 
pressure is applied to the plunger. Figure 1c: counting the number of 
drops until the syringe becomes empty 
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reviewed (Athanasiou et al., 2014), and the interested 
reader is referred to that article.
Home monitoring of blood glucose concentration 
by the owner can be used to create a typical 12h blood 
glucose curve if measurements are made at 2h intervals. 
The theoretical advantages over performing the same 
procedure at the hospital include increased reliability of 
the results since there is no significant change of daily 
routine (feeding, exercise) or interference by the stress 
of hospitalization, and the reduced cost (Alt et al., 2007; 
Roomp and Rand, 2009; Ford and Lynch, 2013). Serial 
blood glucose curves at the hospital suffer from day 
to day variation in both diabetic dogs and cats; their 
repeatability, even when performed on consecutive 
days, is that low that may result in opposite recom-
mendations for adjustment of insulin dose (Alt et al., 
2007; Roomp and Rand, 2009; Ford and Lynch, 2013). 
However, even at the home environment day to day 
variation is also expected, although it is less problem-
atic in well regulated diabetic animals (Alt et al., 2007).
Daily measurement of blood glucose concentra-
tions is also an essential part of the intensive protocols 
aiming at diabetic remission in cats (see later). Also, 
the ability of the owner to measure blood glucose 
concentrations at home may be extremely helpful to 
confirm suspect episodes of hypoglycemia in insulin-
treated dogs and cats (Roomp and Rand, 2009) and also 
enables the use of portable blood ketone monitors that 
can show increased concentrations of b-hydroxyburate 
days before urine dip sticks become positive for ketone 
bodies (Roomp and Rand, 2013).
It is emphasized that the results of home monitor-
ing of blood glucose concentration can be used to 
modify insulin treatment only after consultation with 
the attending clinician or following a predetermined 
dose adjustment protocol (see later). 
CONTINUOUS GLUCOSE MONITORING  
SYSTEMS
A recent addition to our armamentarium for care 
of diabetic pets is the use of continuous glucose moni-
toring systems (CGMSs) that may become standard of 
care in the near future (Rios and Ward, 2008). These 
systems use a small, flexible and disposable sensor that 
is inserted into SC tissue to constantly measure glucose 
concentration in the interstitial fluid with the glucose 
oxidase reaction; since blood and interstitial f luid 
glucose concentrations equilibrate relatively fast (5-12 
min) and CGMSs are calibrated based on the former, 
they have the ability to accurately measure glucose 
concentration every 1-10sec, average and display the 
results every 3-5min and work constantly for up to 
48-144h (Wiedmeyer and DeClue, 2008; Affenzeller et 
al., 2010; Moretti et al., 2010; Affenzeller et al., 2011; 
Dietiker-Moretti et al., 2011; Fleeman, 2011; Hoenig et 
al., 2012; Hafner et al., 2013; Mori et al., 2013; Surman 
and Fleeman, 2013).
There are commercially available CGMSs that dif-
fer in their SC tissue glucose concentration working 
range (20-600 mg dl-1, depending on the device), dura-
tion of the initialization period between insertion of 
the sensor and the first display (0.5-2h), timing of the 
initial and subsequent calibrations, cable or wireless 
connection between the sensor and the monitor, and 
their ability for real-time display of the recordings or 
not (Rios and Ward, 2008; Wiedmeyer and DeClue, 
2008; Affenzeller et al., 2010; Moretti et al., 2010; 
Dietiker-Moretti et al., 2011; Fleeman, 2011; Hafner 
et al., 2013; Surman and Fleeman, 2013). Continuous 
research efforts aim to optimize the site of the body 
where the sensor is inserted into the SC tissue and 
to validate different CGMSs for dogs and cats (Rios 
and Ward, 2008; Affenzeller et al., 2010; Moretti et 
al., 2010; Dietiker-Moretti et al., 2011; Hoenig et al., 
2012; Hafner et al., 2013; Mori et al., 2013; Surman 
and Fleeman, 2013). 
When CGMSs are used, instead of periodic blood 
sampling, they offer distinct advantages, including 
convenience, safety and, most importantly, increased 
accuracy for detection of Somogyi response, true nadir 
and brief periods of hypoglycemia that can be easily 
missed during a typical 12h serial blood glucose curve 
performed during the day if they occur between two 
sequential blood samplings or at night (Martin and 
Rand, 2007b; Rios and Ward, 2008; Wiedmeyer and 
DeClue, 2008; Affenzeller et al., 2010; Moretti et al., 
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daily measurement of blood glucose concentrations 
at home, with a PBGM, at least three (i.e. before each 
insulin injection and then every 3-6h) and usually 4-5 
times per day (i.e. in the morning before meal and 
insulin, one or twice in the middle of the day, in the 
evening before meal and insulin, and at bed time), c) 
checking for ketonuria at home, with urine dip sticks, 
twice daily for the first 3 days and then less frequently, 
and d) re-examinations at the hospital, initially every 
week and then every 2-4 weeks (Roomp and Rand, 
2009, 2012; Ford and Lynch, 2013; Roomp and Rand, 
2013). This protocol includes five phases: the initial 
phase (first 3 days), the second phase where insulin 
dose is gradually increased, the third phase where the 
dose that keeps blood glucose concentrations between 
50 and 200 mg dl-1 throughout the day is administered, 
the fourth phase where the dose is gradually reduced 
and the final phase of diabetic remission (Table 2). 
The only side effect of this protocol is hypoglycemia: 
biochemical hypoglycemia is quite frequent (10-12% 
of the serial blood glucose curves and at least once 
in up to 93% of the cats) but clinical hypoglycemia is 
seemingly rare (2-6% of the cats) and does not occur 
at a higher frequency compared to the traditional non-
intensive treatment protocols (Roomp and Rand, 2009, 
2012; Roomp and Rand, 2013; Surman and Fleeman, 
2013). Also, Somoygi phenomenon is rare although an 
increase in glucose concentrations after each incre-
ment of insulin dose is expected in one fourth of the 
cats, most probably due to a mild counter-regulatory 
response (Roomp and Rand, 2009; Roomp and Rand, 
2013). The major advantage of the protocol is that it 
offers the highest chances for diabetic remission and 
a good regulation of DM when remission cannot be 
achieved (Roomp and Rand, 2009, 2012; Roomp and 
Rand, 2013).
A second, less intense protocol is based on the 
same requirements as the previous one except that 
blood glucose concentrations are measured at home 
every 3-4h for 12h only once per week (less ide-
ally every 2 weeks) instead of daily measurements 
(Roomp and Rand, 2013). Insulin glargine or detemir 
is administered initially at 0.25 or 0.5 U kg-1 BID if 
blood glucose concentration is <360 mg dl-1 or >360 
2010; Affenzeller et al., 2011; Dietiker-Moretti et al., 
2011; Fleeman, 2011; Hoenig et al., 2012; Hafner et al., 
2013; Mori et al., 2013; Surman and Fleeman, 2013). 
Besides the cost of the device, disadvantages of CGMs 
include the possibility of sensor disconnection or foul-
ing, their dependence on accurate calibration based 
on blood glucose concentrations, the possible delay of 
measurement because, depending on the device, cali-
bration is impossible when blood glucose concentration 
is very low (<20-40 mg dl-1) or high (>400-600 mg dl-1) 
and the inaccuracy of the results when used in animals 
with dehydration or under general anesthesia (Rios and 
Ward, 2008; Wiedmeyer and DeClue, 2008; Affenzel-
ler et al., 2010; Moretti et al., 2010; Affenzeller et al., 
2011; Dietiker-Moretti et al., 2011; Hoenig et al., 2012; 
Surman and Fleeman, 2013).
PROTOCOLS TO TIGHTLY CONTROL 
BLOOD GLUCOSE CONCENTRATIONS WITH 
THE AIM OF DIABETIC REMISSION IN CATS
Until some years ago, efforts to tightly control blood 
glucose concentrations in cats with DM were discour-
aged due to the fear of hypoglycemia and lack of infor-
mation on potential benefits. In recent years, protocols 
including administration of long-acting insulin (usually 
glargine and less commonly detemir or PZI), feeding a 
very low carbohydrate diet (≤10%), regular measurement 
of blood glucose concentrations with PBGM at home by 
the owner and changing insulin dose to tightly control 
blood glucose concentrations have been developed, 
offering distinct advantages: safety, better quality of 
life and an impressively high rate of diabetic remission 
(Martin and Rand, 2007a; Marshall et al., 2009; Roomp 
and Rand, 2009, 2012; Ford and Lynch, 2013; Roomp 
and Rand, 2013). It is emphasized that the recommended 
monitoring of cats treated with these protocols must be 
followed very closely in order to avoid hypoglycemia 
which is the most disastrous complication. If this is not 
feasible, it is better to be on the safe side and treat dia-
betic cats with a non-intense protocol, starting with the 
lowest recommended insulin dose. 
The most aggressive published protocol requires: 
a) BID administration of insulin glargine or lente, b) 
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Phase 1: initial treatment (duration: 3 days)
Initial insulin dose: 0.25 U kg-1 every 12h; if the cat had been previously treated with another insulin information from 
the history may be used to increase or decrease the initial dose; if there is a history of ketosis the initial dose is increased 
by 0.5 U per cat
Blood glucose Insulin dose change
>300 mg dl-1 after 24-48h Increase by 0.5 U per cat
<50-60 mg dl-1 at any time Decrease by 0.25-1 U per cat2
Phase 2: gradually increase insulin dose
Blood glucose Insulin dose change
Nadir >300 mg dl-1 Increase by 0.5-1 U per cat every 3 days
Nadir: 200-300 mg dl-1 Increase by 0.25-0.5 U per cat every 3 days
Nadir <200 mg dl-1 and zenith >200 mg dl-1 Increase by 0.25-1 U per cat every 5-7 days
<50-60 mg dl-1 at any time Decrease by 0.25-1 U per cat
<100 mg dl-1 just before insulin Decrease by 0.25-0.5 U per cat, give food or
Give food and wait 1-2h3 or
Give food and 2/3 of insulin and wait 1-2h4
Phase 3: keep blood glucose concentrations 50-200 mg dl-1 throughout the day
Blood glucose Insulin dose change
<50-60 mg dl-1 at any time Decrease by 0.25-1 U per cat
>200 mg dl-1 at any time Increase by 0.25-1 U per cat
Phase 4: gradually decrease insulin dose
Blood glucose Insulin dose change
Nadir <40 mg dl-1 at any time Decrease by 0.25-1 U per cat or by 50%
Nadir: 40-50 mg dl-1 on 3 separate days Decrease by 0.25-1 U per cat
Nadir: 50-100 mg dl-1 every day x 7 days Decrease by 0.25-0.5 U per cat
>200 mg dl-1 at any time Increase to the previously effective dose
Phase 5: achievement of diabetic remission
After gradual dose reductions insulin had been discontinued (e.g. at a dose of 0.25 U per cat nadir was 40-50 mg dl-1 on 3 
separate days) and blood glucose concentrations are measured every week, 1h after feeding
Blood glucose Insulin dose change
>150 mg dl-1 at any measurement Restart at the last effective insulin dose
1Blood glucose concentrations are measured by a portable blood glucose meter (PBGM) intended for use in human whole 
blood. If a veterinary-purpose PBGM or human plasma PBGM is used all reported blood glucose concentrations should be 
increased by 20 mg dl-1
2Throughout this protocol, when a dose change (increment of decrement) of 0.25-1 U per cat is needed, a 0.25 U per cat dose 
change is recommended when the previous dose is low (<3 U per cat) whereas a 0.5-1 U per cat dose change is recommended 
when the previous dose is high (≥3 u per cat) 
3If 1-2 after the meal blood glucose concentration is >100 mg dl-1 the full insulin dose is administered but if it is <100 mg dl-1 
the dose is decreased by 0.25-0.5 U per cat
4If 1-2h after insulin administration blood glucose concentration is >100 mg dl-1 the remaining 1/3 of the dose is administered 
but if it is <100 mg dl-1 the remaining 1/3 of the dose is skipped
Table 2. Intense protocol of insulin glargin or detemir administration and daily monitoring of blood glucose concentrations1 aiming 
to diabetic remission in cats with non-complicated diabetes mellitus (adapted from: Roomp and Rand, 2009; Ford and Lynch, 2013; 
Roomp and Rand, 2013)
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treatment of concurrent hyperadrenocorticism. On 
the contrary, it is currently considered a realistic goal 
in diabetic cats, especially those that are newly diag-
nosed. Diabetic remission is defined as maintenance 
of clinical remission and normal blood glucose con-
centrations (<216 mg dl-1) without insulin injections 
for at least 2-4 weeks and is attributed to the reversal 
of the toxic effect of hyperglycemia on pancreatic b 
cells (Marshall et al., 2009; Zini et al., 2010; Smith 
et al., 2012; Callegari et al., 2013; Gottlieb and Rand, 
2013). The importance of diabetic remission relates to 
the improved quality of life for the diabetic cat and the 
owner, the avoidance of hypoglycemia due to insulin 
administration and the dramatic prolongation of life 
expectancy (Callegari et al., 2013). There are numer-
ous patient and treatment-related factors that have 
been associated with increased or decreased chances 
for diabetic remission, including the age of the cat, 
duration of DM, previous glucocorticoid administra-
tion, clinical and laboratory findings on admission 
and during treatment, treatment protocol and moni-
toring and the diet, since all studies on diabetic remis-
sion included cats fed on a very low carbohydrate diet 
(Gottlieb and Rand, 2013). More specifically, in some 
(Zini et al., 2010) but not all (Tschuor et al., 2011) 
studies, remission was witnessed more frequently in 
mg dl-1, respectively, or at 1 U per cat BID when 
glucose monitoring during the next 3 days is not fea-
sible. During the first week of the treatment the dose 
remains constant except if there is no appreciable 
reduction of blood glucose concentrations (dose incre-
ment) or hypoglycemia (dose decrement). Subsequent 
dose adjustments are based on nadir and glucose con-
centrations before the next insulin injection, observed 
on weekly measurements (Table 3). Also, if clinical 
hypoglycemia is witnessed, insulin dose should be 
reduced by 50% regardless of nadir and pre-insulin 
concentrations (Roomp and Rand, 2013).
When blood glucose concentrations cannot be 
measured by the owner, protocols using insulin glar-
gine (Table 4), PZI (Table 5) or lente (Table 6) are avail-
able (Marshall et al., 2009; Roomp and Rand, 2013). 
However, it is important to note that besides reduced 
efficacy these protocols may be associated with an 
increased incidence of clinical hypoglycemia compared 
to the intense protocols with home monitoring of blood 
glucose concentration (Roomp and Rand, 2013).
Diabetic remission is rare in dogs, with the notable 
exception of a few cases with transient DM occurring 
during pregnancy or diestrus (Cook, 2007) or after 
Nadir Insulin dose change
>180 mg dl-1 Increase by 0.25-1 U per cat
90-180 mg dl-1 Same dose
54-90 mg dl-1 Same dose or decrease by 0.25-0.5 U per cat2
<54 mg dl-1 Decrease by 0.5-1 U per cat3
Pre-insulin blood glucose concentration Insulin dose change
>216 mg dl-1 (and nadir >54 mg dl-1) Increase by 0.25-1 U per cat
180-216 mg dl-1 Same dose or decrease by 0.25-0.5 U per cat2
<180 mg dl-1 Decrease by 0.5-1 U per cat3
1Blood glucose concentrations are measured by a portable blood glucose meter (PBGM) intended for use in human whole 
blood. If a veterinary-purpose PBGM or human plasma PBGM is used all reported blood glucose concentrations should be 
increased by 20 mg dl-1
2The decision to reduce the dose or not should be based on both the nadir and the pre-insulin blood glucose concentrations, the 
concentration before the next scheduled insulin administration, water consumption and urine glucose concentrations
3If the insulin dose is 0.5-1 U per cat, treatment is discontinued and the cat is monitored for sustained diabetic remission or not 
Table 3. Moderately intense protocol of insulin glargin or detemir administration and weekly (or biweekly) monitoring of blood glu-
cose concentrations1 aiming to diabetic remission in cats with non-complicated diabetes mellitus (adapted and modified from Roomp 
and Rand, 2013)
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whereas peripheral neuropathy, high blood cholesterol 
and perhaps very high blood glucose concentrations 
on admission have been linked to a lower incidence of 
remission (Roomp and Rand, 2009; Zini et al., 2010; 
Tschuor et al., 2011; Gottlieb and Rand, 2013). Also, 
the likelihood of remission was higher for cats with 
older cats. Glucocorticoid administration during the 
last 6 months and concurrent diagnosis of pancreatic 
disease have been associated with higher chances 
for remission, even in cats with diabetic ketoacidosis 
(Sieber-Ruckstuhl et al., 2008; Marshall et al., 2009; 
Roomp and Rand, 2009; Gottlieb and Rand, 2013), 
Requirements
Serial blood glucose curves on days 10, 17, 28 and then every 2 weeks
Nadir Insulin dose change
126-162 mg dl-1 Same dose
90-126 mg dl-1 Reduce by 0.5 U per cat
<90 mg dl-1 Reduce by 1 U per cat
Pre-insulin blood glucose concentration Insulin dose change
>252 md dl-1 Increase by 0.5 U per cat
216-252 mg dl-1 Reduce by 0.5 U per cat
<216 mg dl-1 Discontinue and check for remission 
Clinical signs Insulin dose change
Hypoglycemia Reduce by 50%
1Blood glucose concentrations are measured by a portable blood glucose meter (PBGM) intended for use in human whole 
blood. If a veterinary-purpose PBGM or human plasma PBGM is used all reported blood glucose concentrations should be 
increased by 20 mg dl-1
Table 4. Protocol of insulin glargin and in-clinic serial blood glucose curves1 in cats with non-complicated diabetes mellitus (adapted 
and slightly modified from Marshall et al., 2009)
Requirements
Serial blood glucose curves on days 10, 17, 28 and then every 2 weeks
Nadir Insulin dose change
>150 mg dl-1 Increase by 25-100%
80-150 mg dl-1 Same dose
<80 mg dl-1 Reduce by 25-100% or by 1 U per cat
Pre-insulin blood glucose concentration Insulin dose change
>252 md dl-1 Increase by 0.5 U per cat
216-252 mg dl-1 Reduce by 0.5 U per cat
<216 mg dl-1 Discontinue and check for remission 
Clinical signs Insulin dose change
Hypoglycemia Reduce by 50%
1Blood glucose concentrations are measured by a portable blood glucose meter (PBGM) intended for use in human whole 
blood. If a veterinary-purpose PBGM or human plasma PBGM is used all reported blood glucose concentrations should be 
increased by 20 mg dl-1
Table 5. Protocol of insulin PZI and in-clinic serial blood glucose curves1 in cats with non-complicated diabetes mellitus (adapted and 
modified from Marshall et al., 2009; Roomp and Rand, 2013)
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The time frame that diabetic remission occurs 
after treatment initiation is quite variable, ranging 
from less than one month up to more than 1 year, 
but in most cases it is expected during the first 3-4 
months (Martin and Rand, 2007b; Michiels et al., 
2008; Sieber-Ruckstuhl et al., 2008; Dunning et al., 
2009; Hall et al., 2009; Roomp and Rand, 2009; Zini 
et al., 2010; Tschuor et al., 2011; Roomp and Rand, 
2012; Caney, 2013). It is important to remember that 
some cats may present overt clinical signs of DM and 
severe hyperglycemia even 1-2 weeks before remis-
sion (Martin and Rand, 2007b). Diabetic remission 
may be permanent or not, since DM will relapse 
in 0-57% of these cats (Martin and Rand, 2007b; 
Sieber-Ruckstuhl et al., 2008; Dunning et al., 2009; 
Roomp and Rand, 2009; Zini et al., 2010; Roomp 
and Rand, 2012; Caney, 2013; Gottlieb and Rand, 
2013; Roomp and Rand, 2013) and the duration of 
the remission period has been found to be longer in 
heavier cats as well as in cats with lower blood glu-
cose concentrations on diagnosis (Zini et al., 2010). 
In some cases administration of glucocorticoids and 
development of pancreatitis or hyperthyroidism may 
precipitate a relapse whereas in others reappearance 
of DM is attributed to the reduced b-cell mass and 
lower mean blood glucose concentration during a 12h 
serial blood glucose curve after 17 days of treatment 
with insulin glargine, PZI or lente (Marshall et al., 
2009) as well as for cats with lower nadir, mean and 
maximal blood glucose concentrations after 12-16 
weeks of treatment with insulin lente (Michiels et al., 
2008). Intense protocols with regular monitoring of 
blood glucose concentrations and insulin dose adjust-
ments increase the chances for remission (Hall et 
al., 2009; Zini et al., 2010; Gottlieb and Rand, 2013), 
especially when they start in the first 6 months after 
the appearance of clinical signs (Roomp and Rand, 
2009, 2012; Gottlieb and Rand, 2013; Roomp and 
Rand, 2013). Finally, in most studies insulin glargine 
(17-100%) and detemir (42-81%) have been linked 
to increased probability of remission compared to 
insulin PZI (38-68%) or lente (17-63%), while insulin 
glargine can induce remission even in cats unsuc-
cessfully treated with another insulin (Martin and 
Rand, 2007b; Michiels et al., 2008; Rios and Ward, 
2008; Sieber-Ruckstuhl et al., 2008; Hall et al., 2009; 
Marshall et al., 2009; Roomp and Rand, 2009; Zini 
et al., 2010; Tschuor et al., 2011; Roomp and Rand, 
2012; Caney, 2013; Gottlieb and Rand, 2013; Roomp 
and Rand, 2013).
Requirements
Serial blood glucose curves on days 10, 17, 28 and then every 2 weeks
Nadir Insulin dose change
>216 mg dl-1 Increase by 1 U per cat
180-216 mg dl-1 Increase by 0.5 U per cat
126-180 mg dl-1 Same dose
90-126 mg dl-1 Reduce by 0.5 U per cat
54-90 mg dl-1 Reduce by 1 U per cat
<54 mg dl-1 Reduce by 50%
Pre-insulin blood glucose concentration Insulin dose change
<216 mg dl-1 Discontinue and check for remission 
Clinical signs Insulin dose change
Hypoglycemia Reduce by 50%
1Blood glucose concentrations are measured by a portable blood glucose meter (PBGM) intended for use in human whole 
blood. If a veterinary-purpose PBGM or human plasma PBGM is used all reported blood glucose concentrations should be 
increased by 20 mg dl-1
Table 6. Protocol of insulin lente and in-clinic serial blood glucose curves1 in cats with non-complicated diabetes mellitus (adapted 
and modified from Marshall et al., 2009)
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function (Gottlieb and Rand, 2013; Roomp and Rand, 
2013). A second remission is not very likely but may 
be achieved if treatment is instituted early, which 
underlines the importance of weekly measurements 
of blood glucose concentration 1h post-meal in all 
diabetic cats under remission and immediate imple-
mentation of insulin treatment if it exceeds 120-150 
mg dl-1 (Roomp and Rand, 2009; Zini et al., 2010; 
Roomp and Rand, 2012; Ford and Lynch, 2013; Got-
tlieb and Rand, 2013; Roomp and Rand, 2013).
AUTHORS’ NOTE
Not all insulin preparations and equipment men-
tioned in this article are currently commercially avail-
able in Greece. However, commercial availability 
changes over time and practitioners may purchase them 
from internet stores. 
REFERENCES 
Affenzeller N, Benesch T, Thalhammer JG, Willmann M (2010) A 
pilot study to evaluate a novel subcutaneous continuous glucose 
monitoring system in healthy Beagle dogs. Vet J 184: 105-110.
Affenzeller N, Thalhammer JG, Willmann M (2011) Home-based 
subcutaneous continuous glucose monitoring in 10 diabetic dogs. 
Vet Rec 169: 206.
Alt N, Kley S, Haessig M, Reusch CE (2007) Day-to-day variability of 
blood glucose concentration curves generated at home in cats with 
diabetes mellitus. J Am Vet Med Assoc 230: 1011-1017.
Aptekmann KP, Schwartz DS (2011) A survey of owner attitudes and 
experiences in managing diabetic dogs. Vet J 190: e122-124.
Athanasiou LV, Tsokana CN, Saridomichelakis MN (2014) Glucose 
measurement using portable blood glucose meters in dogs and cats. 
J Hell Vet Med Socaccepted for publication.
Callegari C, Mercuriali E, Hafner M, Coppola LM, Guazzetti S, Lutz 
TA, Reusch CE, Zini E (2013) Survival time and prognostic factors 
in cats with newly diagnosed diabetes mellitus: 114 cases (2000-
2009). J Am Vet Med Assoc 243: 91-95.
Caney SM (2013) Management of cats on Lente insulin: tips and traps. 
Vet Clin North Am Small Anim Pract 43: 267-282.
Clark M, Thomaseth K, Heit M, Hoenig M (2012) Pharmacokinetics and 
pharmacodynamics of protamine zinc recombinant human insulin 
in healthy dogs. J Vet Pharmacol Ther 35: 342-350.
Cook AK (2007) The latest management recommendations for cats and 
dogs with nonketotic diabetes mellitus. Vet Med 54: 600-614.
Davison LJ, Walding B, Herrtage ME, Catchpole B (2008) Anti-insulin 
antibodies in diabetic dogs before and after treatment with different 
insulin preparations. J Vet Intern Med 22: 1317-1325.
Dietiker-Moretti S, Müller C, Sieber-Ruckstuhl N, Tschuor F, Osto M, 
Franchini M, Ackermann M, Lutz TA, Reusch CE, Zini E (2011) 
Comparison of a continuous glucose monitoring system with a 
portable blood glucose meter to determine insulin dose in cats with 
diabetes mellitus. J Vet Intern Med 25: 1084-1088.
Dunning MD, Lowrie CS, Bexfield NH, Dobson JM, Herrtage ME 
(2009) Exogenous insulin treatment after hypofractionated 
radiotherapy in cats with diabetes mellitus and acromegaly. J Vet 
Intern Med 23: 243-249.
Fleeman LM (2011) Continuous monitoring of glucose concentration in 
diabetic dogs. Vet Rec 169: 204-205.
Fleeman LM, Rand JS, Morton JM (2009) Pharmacokinetics and 
pharmacodynamics of porcine insulin zinc suspension in eight 
diabetic dogs. Vet Rec 164: 232-237.
Ford SL, Lynch H (2013) Practical use of home blood glucose 
monitoring in feline diabetics. Vet Clin North Am Small Anim Pract 
43: 283-301.
Fracassi F, Boretti FS, Sieber-Ruckstuhl NS, Reusch CE (2012) Use 
of insulin glargine in dogs with diabetes mellitus. Vet Rec 170: 52.
Gilor C, Ridge TK, Attermeier KJ,  Graves TK (2010) 
Pharmacodynamics of insulin detemir and insulin glargine assessed 
by an isoglycemic clamp method in healthy cats. J Vet Intern Med 
24: 870-874.
Gottlieb S, Rand JS (2013) Remission in cats: including predictors and 
risk factors. Vet Clin North Am Small Anim Pract 43: 245-249.
Hafner M, Lutz TA, Reusch CE, Zini E (2013) Evaluation of sensor sites 
for continuous glucose monitoring in cats with diabetes mellitus. J 
Feline Med Surg 15: 117-123.
Hall TD, Mahony O, Rozanski EA, Freeman LM (2009) Effects of diet 
on glucose control in cats with diabetes mellitus treated with twice 
daily insulin glargine. J Feline Med Surg 11: 125-130.
Hess RS, Drobatz KJ (2013) Glargine insulin for treatment of naturally 
occurring diabetes mellitus in dogs. J Am Vet Med Assoc 243: 1154-
1161.
Hoenig M, Pach N, Thomaseth K, Devries F, Ferguson DC (2012) 
Evaluation of long-term glucose homeostasis in lean and obese cats 
by use of continuous glucose monitoring. Am J Vet Res 73: 1100-1106.
Maggiore AD, Nelson RW, Dennis J, Johnson E, Kass PH (2012) 
Efficacy of protamine zinc recombinant human insulin for 
controlling hyperglycemia in dogs with diabetes mellitus. J Vet 
Intern Med 26: 109-115.
Marshall RD, Rand JS, Morton JM (2008) Glargine and protamine zinc 
insulin have a longer duration of action and result in lower mean 
daily glucose concentrations than lente insulin in healthy cats. J Vet 
Pharmacol Ther 31: 205-212.
Marshall RD, Rand JS, Morton JM (2009) Treatment of newly 
diagnosed diabetic cats with glargine insulin improves glycaemic 
control and results in higher probability of remission than protamine 
zinc and lente insulins. J Feline Med Surg 11: 683-691.
Martin GJ, Rand JS (2007a) Comparisons of different measurements 
for monitoring diabetic cats treated with porcine insulin zinc 
suspension. Vet Rec 161: 52-58.
Martin GJ, Rand JS (2007b) Control of diabetes mellitus in cats with 
porcine insulin zinc suspension. Vet Rec 161: 88-94.
Miceli DD, Gallelli MF, Cabrera Blatter MF, Martiarena B, Brañas 
MM, Ortemberg LR, Gómez NV, Castillo VA (2012) Low dose 
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 21/02/2020 05:22:46 |
98  SARIDOMICHELAKIS M.N., CHATZIS M.K.
J HELLENIC VET MED SOC 2016, 67(2)
ΠΕΚΕ 2016, 67(2)
of insulin detemir controls glycaemia, insulinemia and prevents 
diabetes mellitus progression in the dog with pituitary-dependent 
hyperadrenocorticism. Res Vet Sci 93: 114-120.
Michiels L, Reusch CE, Boari A, Petrie G, Mandigers P, Thollot IG, 
Rosenberg D, Mooney C, Bonfanti U, Font A, Sparkes A, Bewig K, 
Clercx C, Jensen AL, Horspool LJ (2008) Treatment of 46 cats with 
porcine lente insulin-a prospective, multicentre study. J Feline Med 
Surg 10: 439-451.
Moretti S, Tschuor F, Osto M, Franchini M, Wichert B, Ackermann M, 
Lutz TA, Reusch CE, Zini E (2010) Evaluation of a novel real-time 
continuous glucose-monitoring system for use in cats. J Vet Intern 
Med 24: 120-126.
Mori A, Kurishima M, Oda H, Saeki K, Arai T, Sako T (2013) 
Comparison of glucose fluctuations between day- and night-time 
measured using a continuous glucose monitoring system in diabetic 
dogs. J Vet Med Sci 75: 113-117.
Mori A, Sako T, Lee P, Motoike T, Iwase K, Kanaya Y, Fukuta H, 
Mizutani H, Arai T (2008) Comparison of time-action profiles of 
insulin glargine and NPH insulin in normal and diabetic dogs. Vet 
Res Commun 32: 563-573.
Nelson RW, Henley K, Cole C, Group. PCS (2009) Field safety and 
efficacy of protamine zinc recombinant human insulin for treatment 
of diabetes mellitus in cats. J Vet Intern Med 23: 787-793.
Niessen SJ, Powney S, Guitian J, Niessen AP, Pion PD, Shaw JA, 
Church DB (2010) Evaluation of a quality-of-life tool for cats with 
diabetes mellitus. J Vet Intern Med 24: 1098-1105.
Niessen SJ, Powney S, Guitian J, Niessen AP, Pion PD, Shaw JA, 
Church DB (2012) Evaluation of a quality-of-life tool for dogs with 
diabetes mellitus. J Vet Intern Med 26: 953-961.
Palm CA, Boston RC, Refsal KR, Hess RS (2009) An investigation of 
the action of Neutral Protamine Hagedorn human analogue insulin 
in dogs with naturally occurring diabetes mellitus. J Vet Intern Med 
23: 50-55.
Rios L, Ward C (2008) Feline diabetes mellitus: diagnosis, treatment, 
and monitoring. Comp Cont Educ Pract 30: 626-640.
Roomp K, Rand J (2009) Intensive blood glucose control is safe and 
effective in diabetic cats using home monitoring and treatment with 
glargine. J Feline Med Surg 11: 668-682.
Roomp K, Rand J (2012) Evaluation of detemir in diabetic cats managed 
with a protocol for intensive blood glucose control. J Feline Med 
Surg 14: 566-572.
Roomp K, Rand JS (2013) Management of diabetic cats with long-acting 
insulin. Vet Clin North Am Small Anim Pract 43: 251-266.
Sako T, Mori A, Lee P, Oda H, Saeki K, Miki Y, Kurishima M, Mimura 
K, Nozawa S, Mizutani H, Makino Y, Ishioka K, Arai T (2011) 
Time-action profiles of insulin detemir in normal and diabetic dogs. 
Res Vet Sci 90: 396-403.
Scott-Moncrieff JC, Moore GE, Coe J, Lynn RC, Gwin W, Petzold 
R (2012) Characteristics of commercially manufactured and 
compounded protamine zinc insulin. J Am Vet Med Assoc 240: 
600-605.
Sieber-Ruckstuhl NS, Kley S, Tschuor F, Zini E, Ohlerth S, Boretti 
FS, Reusch CE (2008) Remission of diabetes mellitus in cats with 
diabetic ketoacidosis. J Vet Intern Med 22: 1326-1332.
Smith JR, Vrono Z, Rapoport GS, Turek MM, Creevy KE (2012) A survey 
of southeastern United States veterinarians’ preferences for managing 
cats with diabetes mellitus. J Feline Med Surg 14: 716-722.
Surman S, Fleeman L (2013) Continuous glucose monitoring in small 
animals. Vet Clin North Am Small Anim Pract 43: 381-406.
Tschuor F, Zini E, Schellenberg S, Wenger M, Kaufmann K, Furrer D, 
Lutz TA, Reusch CE (2011) Remission of diabetes mellitus in cats 
cannot be predicted by the arginine stimulation test. J Vet Intern 
Med 25: 83-89.
Wiedmeyer CE, DeClue AE (2008) Continuous glucose monitoring in 
dogs and cats. J Vet Intern Med 22: 2-8.
Zerrenner D, Peterson M, Crawford MA (2007) The evolution of insulin 
therapy. Comp Cont Educ Pract 29: 522-535.
Zini E, Hafner M, Osto M, Franchini M, Ackermann M, Lutz TA, 
Reusch CE (2010) Predictors of clinical remission in cats with 
diabetes mellitus. J Vet Intern Med 24: 1314-1321.
Powered by TCPDF (www.tcpdf.org)
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 21/02/2020 05:22:46 |
